These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 28755409)

  • 21. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
    Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
    Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
    Gao W; Jusko WJ
    Drug Metab Dispos; 2012 May; 40(5):990-7. PubMed ID: 22338110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects.
    Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC
    Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.
    Elbrønd B; Jakobsen G; Larsen S; Agersø H; Jensen LB; Rolan P; Sturis J; Hatorp V; Zdravkovic M
    Diabetes Care; 2002 Aug; 25(8):1398-404. PubMed ID: 12145241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
    Hua F; Comer GM; Stockert L; Jin B; Nowak J; Pleasic-Williams S; Wunderlich D; Cheng J; Beebe JS
    J Clin Pharmacol; 2014 Jan; 54(1):14-22. PubMed ID: 23913720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study.
    Yang G; Cao B; Yang Y; Geng Y; Lin H; Jiang J; Zhao Y; Weng Z; Zhang C; Bai Y; Li J
    Int J Clin Pharmacol Ther; 2020 Nov; 58(11):608-616. PubMed ID: 32729820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
    Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
    Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers.
    Johnson KW; Neale A; Gordon A; Roessig J; Bezwada P; Vukelich S; Goldfine I; Rubin P
    J Clin Endocrinol Metab; 2017 Aug; 102(8):3021-3028. PubMed ID: 28605468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
    Gu N; Cho SH; Kim J; Shin D; Seol E; Lee H; Lim KS; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2014 Jan; 36(1):101-14. PubMed ID: 24373998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
    He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
    Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.
    Cui H; Zhao CY; Lv Y; Wei MJ; Zhu Y; Ma XZ; Xia YH; Tian JH; Ma Y; Liu Y; Zhang P; Xu M
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):265-275. PubMed ID: 33576936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
    Jain M; Carlson G; Cook W; Morrow L; Petrone M; White NE; Wang T; Naylor J; Ambery P; Lee C; Hirshberg B
    Diabetologia; 2019 Mar; 62(3):373-386. PubMed ID: 30593607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
    Nagy CF; Leach TS; Hoffman JH; Czech A; Carpenter SE; Guttendorf R
    Clin Ther; 2016 Sep; 38(9):2083-2097.e7. PubMed ID: 27568215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
    Vajda EG; Logan D; Lasseter K; Armas D; Plotkin DJ; Pipkin JD; Li YX; Zhou R; Klein D; Wei X; Dilzer S; Zhi L; Marschke KB
    Diabetes Obes Metab; 2017 Jan; 19(1):24-32. PubMed ID: 27501510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
    van Hartingsveldt B; Nnane IP; Bouman-Thio E; Loza MJ; Piantone A; Davis HM; Petty KJ
    Br J Clin Pharmacol; 2013 May; 75(5):1289-98. PubMed ID: 23043368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.